RAC Strategic Regulatory Planning 2 — Questions and Answers
Question 1: Which regulatory strategy is most appropriate when a company needs to launch a product simultaneously in the US, EU, and Japan?
- Sequential submissions to each region independently
- Global regulatory harmonization strategy using ICH guidelines (Correct answer)
- Prioritizing the largest market first before others
- Delegating each region to separate uncoordinated teams
Correct answer: Global regulatory harmonization strategy using ICH guidelines
A global harmonization strategy leveraging ICH guidelines enables concurrent submissions across regions by aligning data packages to shared standards.
Question 2: What is the primary purpose of a Regulatory Affairs Strategic Plan (RASP)?
- To document all adverse events during clinical trials
- To outline regulatory milestones, resources, and risk mitigation for product development (Correct answer)
- To serve as the product labeling master document
- To replace the Quality Management System during development
Correct answer: To outline regulatory milestones, resources, and risk mitigation for product development
A RASP aligns regulatory activities with business objectives by defining milestones, resource needs, and contingency strategies throughout development.
Question 3: A company is developing a combination product (drug-device). Which US regulatory consideration is most critical early in strategic planning?
- Selecting the most favorable market for launch
- Determining the primary mode of action to identify the lead FDA Center (Correct answer)
- Choosing between 510(k) and PMA pathways regardless of the drug component
- Filing only with CDRH since a device is involved
Correct answer: Determining the primary mode of action to identify the lead FDA Center
For combination products, FDA assigns jurisdiction based on primary mode of action (PMOA), determining which Center leads review and which pathway applies.
Question 4: Which tool is commonly used in strategic regulatory planning to assess likelihood and impact of regulatory risks?
- GANTT chart
- Risk matrix (probability × impact grid) (Correct answer)
- SWOT analysis of competitors
- Ishikawa (fishbone) diagram for quality defects
Correct answer: Risk matrix (probability × impact grid)
A risk matrix plots regulatory risks by probability and impact severity, enabling teams to prioritize mitigation efforts strategically.
Question 5: A regulatory team is evaluating whether to seek Breakthrough Therapy Designation. What is the key eligibility criterion?
- The drug must treat a rare disease affecting fewer than 200,000 patients
- Preliminary clinical evidence must show substantial improvement over available therapies for a serious condition (Correct answer)
- The product must already have FDA Fast Track status
- Phase 3 trials must be completed with positive results
Correct answer: Preliminary clinical evidence must show substantial improvement over available therapies for a serious condition
Breakthrough Therapy Designation requires preliminary clinical evidence showing substantial improvement on a clinically meaningful endpoint over existing therapies for a serious condition.
Question 6: In strategic planning for a generic drug, which factor most significantly determines the regulatory pathway in the US?
- The brand drug's patent expiration date and market exclusivity status (Correct answer)
- Whether the active ingredient has been approved in Europe
- The size of the patient population needing the drug
- The manufacturing site's ISO certification status
Correct answer: The brand drug's patent expiration date and market exclusivity status
Patent expiration and exclusivity periods (including 180-day exclusivity for first filers) are central to determining when and how a generic ANDA can be strategically filed.
Question 7: What is the strategic advantage of using a pre-submission meeting (Type B meeting) with FDA during drug development?
- It locks FDA into approving the submission without further review
- It allows sponsors to align on study designs, endpoints, and data requirements before costly investments (Correct answer)
- It substitutes for formal Phase 2 clinical trial requirements
- It guarantees expedited review timelines post-submission
Correct answer: It allows sponsors to align on study designs, endpoints, and data requirements before costly investments
Type B meetings (including End-of-Phase 2 and pre-NDA meetings) allow sponsors to gain FDA feedback on development plans before committing resources, reducing submission risk.
RAC Strategic Regulatory Planning 2
Which regulatory strategy is most appropriate when a company needs to launch a product simultaneously in the US, EU, and Japan?